Skip to main content
锦波生物 logo

锦波生物 — Investor Relations & Filings

Ticker · 920982 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 391 across all filing types
Latest filing 2025-05-13 Capital/Financing Update
Country CN China
Listing Beijing Stock Exchange 920982

About 锦波生物

https://www.sxjbswyy.com/

Shanxi Jinbo Bio-Pharmaceutical Co., Ltd. specializes in the research, development, and manufacturing of functional proteins through synthetic biology. The company is recognized for its industrialization of recombinant humanized collagen, specifically Type III collagen with a stable triple helix structure. Its core business encompasses the production of medical-grade biomaterials, functional skincare products, and medical devices used in aesthetics, wound healing, and gynecological health. By utilizing advanced protein engineering, the company provides biocompatible solutions designed for tissue repair and anti-aging applications. Its technical focus remains on the structural optimization and large-scale production of high-purity recombinant proteins to meet clinical and consumer health demands.

Recent filings

Filing Released Lang Actions
2025年股票期权激励计划首次授予激励对象名单（首次授予日）
Capital/Financing Update Classification · 95% confidence The document is a public announcement from Shanxi Jinbo Biopharmaceutical Co., Ltd. regarding the initial grant list of stock option incentives under the 2025 stock option incentive plan. It includes detailed allocation data and names of incentive recipients. The content focuses on stock option grants to employees and executives, which is a capital-related update about share-based compensation. It is not a full financial report, earnings release, or management discussion. It is also not a regulatory certification or voting result. Given the nature of the announcement about stock option grants, the most appropriate classification is Capital/Financing Update (CAP). The document length is short (1666 characters), but it contains substantive information about the stock option plan grant, not just a notice of report publication or a certification. Therefore, CAP is the best fit with high confidence.
2025-05-13 Chinese
2025年第一次临时股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2025 first extraordinary shareholders meeting of Shanxi Jinbo Biopharmaceutical Co., Ltd. It includes information about the meeting date, attendance, voting results on various proposals related to the 2025 stock option incentive plan, and legal opinions confirming the legality of the meeting and voting process. The document focuses on the voting results and decisions made by shareholders rather than presenting financial data or management discussion. It is not an annual or interim report, earnings release, or management report. It is not a proxy solicitation or investor presentation. The content fits the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially reports the voting outcomes of shareholder resolutions at a general meeting. The document length is 3209 characters, which is consistent with a detailed voting results announcement rather than a full report. Therefore, the correct classification is DVA with high confidence.
2025-05-11 Chinese
关于山西锦波生物医药股份有限公司2025年第一次临时股东会的法律意见书
Regulatory Filings
2025-05-11 Chinese
关于2025年股票期权激励计划内幕信息知情人买卖公司股票情况的自查报告
Regulatory Filings Classification · 95% confidence The document is a self-inspection report regarding insider trading activities related to the company's 2025 stock option incentive plan. It details the investigation scope, procedures, and findings about insider trading by persons aware of the insider information. The document includes a table of stock transactions by insiders and concludes no insider trading or information leakage occurred. It is a regulatory compliance disclosure related to insider trading and stock option plans, not a financial report, earnings release, or management report. It does not announce voting results, board changes, or capital changes. It is a specific regulatory filing about insider trading self-inspection under stock incentive plan rules. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length is short and focused on compliance and disclosure, not a full report or announcement of a report publication.
2025-05-11 Chinese
监事会关于2025年股票期权激励计划首次授予激励对象名单的核查意见及公示情况说明
Regulatory Filings Classification · 95% confidence The document is a formal announcement from Shanxi Jinbo Biopharmaceutical Co., Ltd. regarding the supervisory board's verification and public disclosure of the initial list of incentive recipients under the company's 2025 stock option incentive plan. It references relevant laws and regulations, the company's internal procedures, and confirms the legitimacy and compliance of the incentive recipients. The document does not contain financial statements or detailed financial data, nor is it a report or presentation. It is an official announcement related to stock option incentives and compliance verification, which fits best under Regulatory Filings (RNS) as it does not match other more specific categories like Capital/Financing Update or Director's Dealing. The document length is short (1587 characters), and it is not a report publication announcement. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2025-05-06 Chinese
第四届董事会第十次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 10th meeting of the 4th Board of Directors of Shanxi Jinbo Biopharmaceutical Co., Ltd. It details the meeting logistics, attendance, and voting results on two main agenda items: the adjustment of the Board's Strategic Committee to include Sustainable Development responsibilities, and the approval of the 2024 Sustainability Report. The document references that the full sustainability report is published separately on the Beijing Stock Exchange information disclosure platform, indicating this document is an announcement of board decisions rather than the report itself. The content focuses on board/management decisions and governance changes, specifically related to board committee restructuring and sustainability reporting. Therefore, the document fits best under Board/Management Information (MANG) as it announces changes in board committee structure and related governance matters, rather than being the sustainability report itself or a general governance report. The document length is short (1689 characters), consistent with an announcement rather than a full report.
2025-04-29 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.